{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:08:25Z","timestamp":1794380905459,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06236"],"award-info":[{"award-number":["JP23K06236"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019890","name":"University of Miyazaki Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87801-2","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:24:23Z","timestamp":1737984263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis"],"prefix":"10.1038","volume":"15","author":[{"given":"Naoki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukina","family":"Ehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"87801_CR1","doi-asserted-by":"crossref","unstructured":"Gooptu, M. & Antin, J. H. GVHD Prophylaxis 2020. Front. Immunol. 12, 605726 (2021).","DOI":"10.3389\/fimmu.2021.605726"},{"key":"87801_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson, A. W., Bonham, C. A. & Zeevi, A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther. Drug Monit. 17, 584\u2013591 (1995).","journal-title":"Ther. Drug Monit."},{"key":"87801_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00003495-200059020-00021","volume":"59","author":"GL Plosker","year":"2000","unstructured":"Plosker, G. L. & Foster, R. H. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59, 323\u2013389 (2000).","journal-title":"Drugs"},{"key":"87801_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/bbmt.1999.v5.pm10371361","volume":"5","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka, D. et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol. Blood Marrow Transpl. 5, 94\u201397 (1999).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"87801_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17425255.2019.1675635","volume":"15","author":"Y Gao","year":"2019","unstructured":"Gao, Y. & Ma, J. Tacrolimus in adult hematopoietic stem cell transplantation. Expert Opin. Drug Metab. Toxicol. 15, 803\u2013811 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"87801_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/cpt.1618","volume":"107","author":"DRJ Kuypers","year":"2020","unstructured":"Kuypers, D. R. J. Intrapatient variability of Tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome. Clin. Pharmacol. Ther. 107, 347\u2013358 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"87801_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/ph14040353","volume":"14","author":"N Yoshikawa","year":"2021","unstructured":"Yoshikawa, N. et al. Relationship between CYP3A5 polymorphism and Tacrolimus Blood concentration changes in allogeneic hematopoietic stem cell transplant recipients during continuous infusion. Pharmaceuticals (Basel). 14, 353 (2021).","journal-title":"Pharmaceuticals (Basel)"},{"key":"87801_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","volume":"115","author":"T Nakashima","year":"2022","unstructured":"Nakashima, T. et al. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. Int. J. Hematol. 115, 158\u2013162 (2022).","journal-title":"Int. J. Hematol."},{"key":"87801_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1136\/ejhpharm-2018-001663","volume":"27","author":"N Yoshikawa","year":"2020","unstructured":"Yoshikawa, N. et al. Retrospective analysis of the correlation between tacrolimus concentrations measured in whole blood and variations of blood cell counts in patients undergoing allogeneic haematopoietic stem cell transplantation. Eur. J. Hosp. Pharm. 27, e7\u2013e11 (2020).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"87801_CR10","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms20102413","volume":"20","author":"K Suetsugu","year":"2019","unstructured":"Suetsugu, K. et al. Impact of CYP3A5, POR, and CYP2C19 polymorphisms on Trough Concentration to dose ratio of Tacrolimus in Allogeneic hematopoietic stem cell transplantation. Int. J. Mol. Sci. 20, 2413 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"87801_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/pharmaceutics14020379","volume":"14","author":"G Coste","year":"2022","unstructured":"Coste, G. & Lemaitre, F. The role of Intra-patient variability of Tacrolimus drug concentrations in solid organ transplantation: a Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics 14, 379 (2022).","journal-title":"Pharmaceutics"},{"key":"87801_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/bcpt.13803","volume":"132","author":"W Song","year":"2023","unstructured":"Song, W. et al. Lower tacrolimus time in therapeutic range is associated with inferior outcomes in adult liver transplant recipients. Basic. Clin. Pharmacol. Toxicol. 132, 51\u201359 (2023).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"87801_CR13","first-page":"42","volume":"46","author":"Q Lao","year":"2024","unstructured":"Lao, Q. et al. Effect of Tacrolimus Time in Therapeutic Range on postoperative recurrence in patients undergoing liver transplantation for Liver Cancer. Ther. Drug Monit. 46, 42\u201348 (2024).","journal-title":"Ther. Drug Monit."},{"key":"87801_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12882-023-03188-0","volume":"24","author":"TVA Nguyen","year":"2023","unstructured":"Nguyen, T. V. A. et al. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation. BMC Nephrol. 24, 131 (2023).","journal-title":"BMC Nephrol."},{"key":"87801_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40780-022-00256-9","volume":"8","author":"Y Katada","year":"2022","unstructured":"Katada, Y. et al. Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. J. Pharm. Heal care Sci. 8, 25 (2022).","journal-title":"J. Pharm. Heal care Sci."},{"key":"87801_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/phar.2653","volume":"42","author":"SK Adie","year":"2022","unstructured":"Adie, S. K. et al. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. Pharmacotherapy 42, 106\u2013111 (2022).","journal-title":"Pharmacotherapy"},{"key":"87801_CR17","doi-asserted-by":"publisher","first-page":"e14291","DOI":"10.1111\/ctr.14291","volume":"35","author":"AD Santeusanio","year":"2021","unstructured":"Santeusanio, A. D., Gu, A., Weinberg, A. D., Moon, J. & Iyer, K. R. Tacrolimus time-in-therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation. Clin. Transpl. 35, e14291 (2021).","journal-title":"Clin. Transpl."},{"key":"87801_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/TP.0000000000002913","volume":"104","author":"S Davis","year":"2020","unstructured":"Davis, S. et al. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and risk of De Novo Donor-Specific antibodies. Transplantation 104, 881\u2013887 (2020).","journal-title":"Transplantation"},{"key":"87801_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet, M. et al. Therapeutic drug monitoring of Tacrolimus-Personalized Therapy: second Consensus Report. Ther. Drug Monit. 41, 261\u2013307 (2019).","journal-title":"Ther. Drug Monit."},{"key":"87801_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/jcpt.13753","volume":"47","author":"JM Hartinger","year":"2022","unstructured":"Hartinger, J. M., Ry\u0161\u00e1nek, P., Slana\u0159, O. & \u0160\u00edma, M. Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients. J. Clin. Pharm. Ther. 47, 1362\u20131367 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"key":"87801_CR21","doi-asserted-by":"crossref","unstructured":"Jorga, A., Holt, D. W. & Johnston, A. Therapeutic drug monitoring of cyclosporine. Transplant. Proc. 36, S396\u2013S403 (2004).","DOI":"10.1016\/j.transproceed.2004.01.013"},{"key":"87801_CR22","doi-asserted-by":"publisher","first-page":"106882","DOI":"10.1016\/j.ejps.2024.106882","volume":"204","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Population pharmacokinetics of cyclosporine A in hematopoietic stem cell transplant recipients: a systematic review. Eur. J. Pharm. Sci. 204, 106882 (2024).","journal-title":"Eur. J. Pharm. Sci."},{"key":"87801_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbmt.2011.08.016","volume":"18","author":"R Ram","year":"2012","unstructured":"Ram, R. et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 18, 414\u2013422 (2012).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"87801_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/bmt.2015.323","volume":"51","author":"A Ganetsky","year":"2016","unstructured":"Ganetsky, A. et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transpl. 51, 568\u2013572 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"87801_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41409-018-0267-5","volume":"54","author":"PA Hagen","year":"2019","unstructured":"Hagen, P. A., Adams, W., Smith, S., Tsai, S. & Stiff, P. Low mean post-transplantation tacrolimus levels in weeks 2\u20133 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transpl. 54, 155\u2013158 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"87801_CR26","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade, J. et al. Post-transplantation Cyclophosphamide-based graft-versus-host Disease Prophylaxis. N Engl. J. Med. 388, 2338\u20132348 (2023).","journal-title":"N Engl. J. Med."},{"key":"87801_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transpl. 14, 641\u2013650 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"87801_CR28","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/bmt.2009.360","volume":"45","author":"E Willems","year":"2010","unstructured":"Willems, E. et al. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transpl. 45, 1442\u20131448 (2010).","journal-title":"Bone Marrow Transpl."},{"key":"87801_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.bbmt.2008.04.002","volume":"14","author":"CL Kitko","year":"2008","unstructured":"Kitko, C. L. et al. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol. Blood Marrow Transpl. 14, 759\u2013765 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"87801_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood-2008-02-138867","volume":"112","author":"SW Choi","year":"2008","unstructured":"Choi, S. W. et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112, 1539\u20131542 (2008).","journal-title":"Blood"},{"key":"87801_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/bmt.2010.165","volume":"46","author":"KJ August","year":"2011","unstructured":"August, K. J. et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transpl. 46, 601\u2013604 (2011).","journal-title":"Bone Marrow Transpl."},{"key":"87801_CR32","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.bbmt.2010.05.001","volume":"16","author":"D Liu","year":"2010","unstructured":"Liu, D. et al. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol. Blood Marrow Transpl. 16, 1567\u20131575 (2010).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"87801_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal, F. R., Cannegieter, S. C., Van Der Meer, F. J. M. & Briet, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236\u2013239 (1993).","journal-title":"Thromb. Haemost"},{"key":"87801_CR34","unstructured":"Guidelines of the Japanese Society for Transplantation and Cellular Therapy GVHD. 5th edition. Japanese Society for Transplantation and Cellular Therapy. (2022). https:\/\/www.jstct.or.jp\/uploads\/files\/guideline\/01_02_gvhd_ver05.1.pdf"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87801-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:24:27Z","timestamp":1737984267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87801"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87801-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3364"}}